ARQT Share Price Performance
US$21.15
7.57 (55.74%)
38.9% undervalued intrinsic discount
US$34.63
Fair Value
Price US$21.15
AnalystConsensusTarget US$34.63
Coward_Nutlick US$39.99
Fair ValueUS$34.63
Share Pricen/a
Narrative Update • May 18
Arcutis Biotherapeutics, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 60 Fair Values set on narratives written by author
ARQT Community Narratives
AN
Fair Value
·Fair Value US$34.63 38.9% undervalued intrinsic discount
Analysts Cite Strong Sales and Pipeline as Arcutis Biotherapeutics Price Target Rises
0users have liked this narrative
0users have commented on this narrative
31users have followed this narrative
CO
Fair Value
·Fair Value US$39.99 47.1% undervalued intrinsic discount
Very Bullish
4users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
Very Bullish
It is almost impossible to obtain a drug label from the FDA for pediatric use - this topical non-steroidal drug ZORYVE is very safe and highly effective for both pediatric and adult patients. The drug is potent in the skin, it is not well absorbed and is quickly metabolized which limits systemic exposure and minimizes side effect risks.Read more
CO
US$39.99
47.1% undervalued intrinsic discount
Fair Value
Profit Margin
21.21%
Future PE
29.38x
Price in 2030
US$55.82
Analysts Cite Strong Sales and Pipeline as Arcutis Biotherapeutics Price Target Rises
Arcutis is betting that its ZORYVE skin treatment can win patients who want options beyond steroids, as it expands into new age groups and additional skin conditions. The big question is whether the company can keep that momentum while relying so heavily on one product and facing insurance hurdles and rising competition.Read more
AN
US$34.63
38.9% undervalued intrinsic discount
Fair Value
Profit Margin
32.98%
Future PE
22.31x
Price in 2029
US$42.32
Trending Discussion
Recently Updated Narratives
CO
Very Bullish
Fair Value: US$39.99 47.1% undervalued intrinsic discount
11 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
1 likeusers have liked this narrative
AN
ARQT: Q4 Execution And 2026 Revenue Guidance Will Support Further Upside
Fair Value: US$34.63 38.9% undervalued intrinsic discount
31 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Arcutis Biotherapeutics, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -0.019
- 90.94%
- -0.57%
- 57.7%
About ARQT
- Founded
- 2016
- Employees
- 354
- CEO
- WebsiteView website
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company’s lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Recent ARQT News & Updates
Seeking Alpha • May 15
